The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Checkpoint inhibitors administered before and after allo-HSCT may increase the risk of graft-versus-host disease
Awais Ijaz from the University of Arizona, Tucson, AZ, USA, and colleagues retrospectively evaluated the safety, efficacy and risks of checkpoint inhibitors (CPIs) in patients with hematological malignancies undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). CPIs can enhance graft versus tumor (GVT) effect, whereas the risk of graft-versus-host disease (GvHD) may increase. The study was published in Biology of Blood and Marrow Transplantation.
Twenty-four articles (13 case reports and 11 original manuscripts) were selected from PubMed regarding CPIs administered for patients with hematological malignancies either before or after allo-HSCT.
Study overview
- N = 283 patients
- Original articles
- CPI was administered before allo-HSCT in 107 patients
- N = 91 patients received nivolumab
- N = 11 patients received pembrolizumab
- N = 8 patients received ipilimumab
- CPI was administered after allo-HSCT in 150 patients
- N = 62 patients received nivolumab
- N = 85 patients received ipilimumab
- N = 4 patients received pembrolizumab
- Case reports
- CPI was administered after allo-HSCT in 26 patients
- N = 14 patients received nivolumab
- N = 12 patients received pembrolizumab
- CPI was administered after allo-HSCT in 26 patients
- CPI was administered before allo-HSCT in 107 patients
Key findings
Data from original articles
- Safety and efficacy when CPI was given prior to allo-HSCT
- GvHD
- Hyper-acute GvHD: 8 patients (7%)
- Acute GvHD: 60 patients (56%)
- Chronic GvHD: 20 patients (29%)
- Overall response rate (ORR) in 62 evaluable patients: 68% (42/62)
- Complete response (CR): 47% (29/62)
- Partial response (PR): 21% (13/62)
- Stable disease (SD): 11% (7/62)
- Progressive disease (PD): 19% (12/62)
- Twenty patients died, 12 deaths occurred due to GvHD
- GvHD
- Safety and efficacy when CPI was given after allo-HSCT
- GvHD
- Acute GvHD: 19 patients (13%)
- Chronic GvHD: 7 patients (11%)
- ORR: 59 patients (48%)
- CR: 34 patients (28%)
- PR: 25 patients (20%)
- SD: 7 patients (6 %)
- PD: 4 patients (3%)
- Thirty-five patients died, 10 deaths were GvHD related
- GvHD
Data from case reports
- Safety and efficacy when CPI was given after allo-HSCT
- CR: 15 patients (58%)
- PR: 7 patients (30%)
- SD: 1 patient (4%)
- PD: 1 patient (4%)
- GvHD
- Acute GvHD: 5 patients (19%)
- One patient (4%) had an exacerbation of existing GvHD
- 15% of patients died, one of them due to GvHD
The authors concluded that the rate of acute GvHD was high (56%) in patients who received CPI therapy prior to allo-HSCT. They added that “this rate is higher than the historical incidence that ranges between 26% to 50%.” In addition, CPIs received after allo-HSCT led to superior efficacy, but also increased the risk of GvHD (14% acute, 9% chronic). The study group further stated that “there is need for extreme caution while making decisions regarding the use of CPI.” Further prospective clinical trials are required to confirm these findings.
References